He Zhou
HiFiBiO Therapeutics (United States)(US)Hang Seng University of Hong Kong(HK)
Publications by Year
Research Areas
SARS-CoV-2 and COVID-19 Research, Monoclonal and Polyclonal Antibodies Research, Cancer Research and Treatments, Cancer Immunotherapy and Biomarkers, Computational Drug Discovery Methods
Most-Cited Works
- → A Pharmacogenomic Landscape in Human Liver Cancers(2019)213 cited
- → High-throughput functional screening for next-generation cancer immunotherapy using droplet-based microfluidics(2021)108 cited
- → A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes(2021)103 cited
- → Local Gene Delivery for Cancer Therapy(2011)24 cited
- → High throughput functional screening for next generation cancer immunotherapy using droplet-based microfluidics(2020)7 cited
- → A SARS-CoV-2 neutralizing antibody with exceptional spike binding coverage and optimized therapeutic potentials(2020)4 cited
- → Abstract 3851: Novel small-molecule inhibitor of PD1/PDL1 pathway demonstrated single agent and drug combo effectiveness in cancer immunotherapy(2018)4 cited
- → Abstract 5675: A novel PI3K inhibitor suppresses tumor progression by immune modulation(2017)3 cited
- → Profiling B cell immune responses to identify neutralizing antibodies from convalescent COVID-19 patients(2020)1 cited
- → Abstract B048: A novel PI3K delta inhibitor suppresses tumor progression by immune modulation(2016)1 cited